BPIFA3: A Potential Drug Target for Various Diseases (G128861)

Target Name: BPIFA3

NCBI ID: G128861

BPIFA3

Other Name(s): C20orf71 | BPI fold-containing family A member 3 | BPIFA3 variant 1 | BPI fold containing family A member 3 | SPLUNC3 | BPI fold containing family A member 3, transcript variant 2 | Short palate, lung and nasal epithelium carcinoma-associated protein 3 | short long palate, lung and nasal epithelium carcinoma associated 3 | BPI fold-containing family A member 3 (isoform 1) | BPIA3_HUMAN | BPI fold-containing family A member 3 (isoform 2) | Short long palate, lung and nasal epithelium carcinoma associated 3 | BPI fold containing family A member 3, transcript variant 1 | BPIFA3 variant 2 | BPI fold-containing family A member 3 precursor

BPIFA3: A Potential Drug Target for Various Diseases

BPIFA3 (C20orf71) is a protein that is expressed in various tissues throughout the body. It is a member of the B-cell maturation antigen (BCMA) family, which is a glycoprotein that is expressed in the bone marrow and other tissues. BPIFA3 is also known as CD11b, and it is a cell surface protein that is involved in the development and maintenance of B cells, as well as other immune cells.

Recent studies have identified BPIFA3 as a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This is because BPIFA3 has been shown to play a role in the regulation of immune cell function, and it is involved in the development and destruction of immune cells.

One of the reasons why BPIFA3 is considered a potential drug target is because it is involved in the regulation of T cell function. T cells are a type of immune cell that play a critical role in the immune response against infections and cancer. BPIFA3 has been shown to regulate the development and function of T cells, and it is possible that it could be used to treat T cell-related diseases.

Another reason why BPIFA3 is considered a potential drug target is because it is involved in the regulation of B cell function. B cells are another type of immune cell that play a critical role in the immune response against infections and cancer. BPIFA3 has been shown to regulate the development and function of B cells, and it is possible that it could be used to treat B cell-related diseases.

BPIFA3 is also a potential biomarker for several diseases, including cancer. This is because it is often expressed in the cells that are affected by the disease, and it can be used as a diagnostic marker for certain diseases. For example, BPIFA3 has been shown to be expressed in the cells of patients with various cancers, including breast, lung, and ovarian cancers. This suggests that it could be used as a potential biomarker for these diseases.

In addition to its potential clinical applications, BPIFA3 is also a potential drug target because it is involved in the regulation of immune cell function. This makes it an attractive target for small molecules, which are often used as drugs to treat diseases.BPIFA3 has been shown to be sensitive to small molecules, and it is possible that a small molecule drug could be used to inhibit its function.

BPIFA3 is also a potential drug target because it is involved in the regulation of cell signaling pathways. This makes it an attractive target for drugs that target signaling pathways, which are the chemical pathways that cells use to communicate with each other.BPIFA3 has been shown to be involved in several signaling pathways, including the JAK/STAT signaling pathway and the NF-kappa-B signaling pathway. This suggests that it is possible that a drug that targets one of these pathways could be used to treat various diseases.

BPIFA3 is also a potential drug target because it is involved in the regulation of cell adhesion. This makes it an attractive target for drugs that target cell adhesion, which is the process by which cells stick together to form tissues and organs.BPIFA3 has been shown to be involved in cell adhesion, and it is possible that a drug that targets this process could be used to treat various diseases.

In conclusion, BPIFA3 is a protein that is expressed in various tissues throughout the body. It is a member of the B-cell maturation antigen (BCMA) family, and it is involved in the development and maintenance of B cells, as well as other immune cells. Recent studies have identified BPIFA3 as a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This is because BPIFA3 has been shown to play

Protein Name: BPI Fold Containing Family A Member 3

The "BPIFA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BPIFA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets